China Shineway Pharmaceutical Group Future Growth
Future criteria checks 2/6
China Shineway Pharmaceutical Group is forecast to grow earnings and revenue by 9.8% and 11.8% per annum respectively. EPS is expected to grow by 9.4% per annum. Return on equity is forecast to be 15.2% in 3 years.
Key information
9.8%
Earnings growth rate
9.4%
EPS growth rate
Pharmaceuticals earnings growth | 19.4% |
Revenue growth rate | 11.8% |
Future return on equity | 15.2% |
Analyst coverage | Low |
Last updated | 03 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 5,603 | 1,401 | 1,248 | 1,371 | 4 |
12/31/2025 | 4,914 | 1,201 | 1,033 | 1,134 | 4 |
12/31/2024 | 4,384 | 1,115 | 859 | 1,177 | 4 |
6/30/2024 | 4,205 | 1,105 | 1,072 | 1,175 | N/A |
3/31/2024 | 4,361 | 1,037 | 930 | 1,054 | N/A |
12/31/2023 | 4,517 | 970 | 788 | 933 | N/A |
9/30/2023 | 4,525 | 926 | 795 | 957 | N/A |
6/30/2023 | 4,534 | 883 | 801 | 982 | N/A |
3/31/2023 | 4,242 | 803 | 891 | 1,046 | N/A |
12/31/2022 | 3,951 | 723 | 980 | 1,110 | N/A |
9/30/2022 | 3,718 | 651 | 814 | 941 | N/A |
6/30/2022 | 3,485 | 579 | 648 | 772 | N/A |
3/31/2022 | 3,354 | 568 | 629 | 738 | N/A |
12/31/2021 | 3,224 | 557 | 610 | 703 | N/A |
9/30/2021 | 3,122 | 453 | 609 | 690 | N/A |
6/30/2021 | 3,020 | 350 | 608 | 677 | N/A |
3/31/2021 | 2,838 | 322 | 590 | 658 | N/A |
12/31/2020 | 2,656 | 295 | 573 | 639 | N/A |
9/30/2020 | 2,592 | 382 | 485 | 561 | N/A |
6/30/2020 | 2,528 | 469 | 397 | 483 | N/A |
3/31/2020 | 2,617 | 486 | 337 | 426 | N/A |
12/31/2019 | 2,706 | 503 | 277 | 368 | N/A |
9/30/2019 | 2,670 | 520 | 289 | 382 | N/A |
6/30/2019 | 2,633 | 537 | 301 | 396 | N/A |
3/31/2019 | 2,602 | 521 | 347 | 465 | N/A |
12/31/2018 | 2,570 | 506 | 393 | 533 | N/A |
9/30/2018 | 2,492 | 516 | 390 | 521 | N/A |
6/30/2018 | 2,413 | 526 | 388 | 509 | N/A |
3/31/2018 | 2,166 | 489 | N/A | 500 | N/A |
12/31/2017 | 1,920 | 452 | N/A | 491 | N/A |
9/30/2017 | 1,897 | 474 | N/A | 588 | N/A |
6/30/2017 | 1,873 | 496 | N/A | 685 | N/A |
3/31/2017 | 1,933 | 542 | N/A | 709 | N/A |
12/31/2016 | 1,993 | 589 | N/A | 734 | N/A |
9/30/2016 | 1,935 | 569 | N/A | 709 | N/A |
6/30/2016 | 1,877 | 549 | N/A | 685 | N/A |
3/31/2016 | 1,966 | 603 | N/A | 715 | N/A |
12/31/2015 | 2,055 | 658 | N/A | 745 | N/A |
9/30/2015 | 2,147 | 672 | N/A | 723 | N/A |
6/30/2015 | 2,239 | 685 | N/A | 701 | N/A |
3/31/2015 | 2,234 | 695 | N/A | 737 | N/A |
12/31/2014 | 2,229 | 705 | N/A | 773 | N/A |
9/30/2014 | 2,228 | 704 | N/A | 740 | N/A |
6/30/2014 | 2,227 | 703 | N/A | 706 | N/A |
3/31/2014 | 2,207 | 693 | N/A | 613 | N/A |
12/31/2013 | 2,187 | 684 | N/A | 520 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: C1S's forecast earnings growth (9.8% per year) is above the savings rate (0.8%).
Earnings vs Market: C1S's earnings (9.8% per year) are forecast to grow slower than the German market (20.2% per year).
High Growth Earnings: C1S's earnings are forecast to grow, but not significantly.
Revenue vs Market: C1S's revenue (11.8% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: C1S's revenue (11.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: C1S's Return on Equity is forecast to be low in 3 years time (15.2%).